Whereas a number of current therapeutic strategies aim to target cancer stem cells63,64, we chose to block NANOG function in human GBM since it is a key transcription factor that specifically regulates stemness in multiple contexts18,25,27. This evidence concerns the gene NANOG and glioblastoma.